Evidence map›Paper›PMID 38775829›Full record

ReviewHNO2024

Organoids-the key to novel therapies for the inner ear?

Marc Diensthuber, Timo Stöver

Abstract readReview
PubMed Publisher
In one paragraph

Review in HNO, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Marc DiensthuberUniversity Hospital, Department of Otorhinolaryngology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany. Diensthuber@med.uni-frankfurt.de.
Timo StöverUniversity Hospital, Department of Otorhinolaryngology, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt/M, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The sensitivity and the complexity of the human inner ear in conjunction with the lack of regenerative capacity are the main reasons for hearing loss and tinnitus. Progress in the development of protective and regenerative therapies for the inner ear often failed in the past not least due to the fact that no suitable model systems for cell biological and pharmacological in vitro studies were available. A novel technology for creating "mini-organs", so-called organoids, could solve this problem and has now also reached inner ear research. It makes it possible to produce inner ear organoids from cochlear stem/progenitor cells, embryonic and induced pluripotent stem cells that mimic the structural characteristics and functional properties of the natural inner ear. This review focuses on the biological basis of these inner ear organoids, the current state of research and the promising prospects that are now opening up for basic and translational inner ear research.

Indexed as

Ear, InnerOrganoidsAnimalsHumansLabyrinth DiseasesRegenerative MedicineStem Cell TransplantationTissue EngineeringHair cellsHearing lossRegenerationStem cellsTinnitus

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.